Hormonal
Unimolecular polyagonists (e.g., GLP-1/Glucagon dual agonists) achieve superior weight loss and glycemic control compared to monoagonists or historical single-target therapies by combining anorectic and thermogenic effects.
Modern obesity treatment is shifting from single-target drugs to 'polyagonists' that activate multiple metabolic pathways (like GLP-1 and Glucagon) simultaneously. This approach is more effective than older single-hormone drugs because it combines appetite suppression with increased energy burning, aiming to match the results of bariatric surgery without the surgery itself.
In 2009, the generation of a single molecule with agonism at the receptors for glucagon and the glucagon-like peptide 1 broke new ground in obesity pharmacology. This molecule combined the beneficial anorectic and glycemic effects of glucagon-like peptide 1 with the thermogenic effect of glucagon into a single molecule with enhanced potency and sustained action.
Why this rating
Based on a comprehensive review of preclinical and clinical data for multiple polyagonists, though specific large-scale human trial results are summarized rather than presented as primary data.
Source
Anti-Obesity Therapy: from Rainbow Pills to Polyagonists
Timo D. Müller et al. · Pharmacological Reviews · 2018
DOI 10.1124/pr.117.014803
More from this paper
- Bariatric surgery (RYGB/VSG) provides superior sustained weight loss (13-27%) and T2D remission compared to pharmacological interventions, largely driven by endocrine changes rather than just mechanical restriction.Strong
- Historical weight-loss drugs (Thyroid hormones, DNP, Amphetamines) failed due to narrow therapeutic windows and severe adverse effects, despite some efficacy.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →